Everist Genomics Discovers Genes Responsible for Recurrence of Colorectal Cancer
Researchers at Everist Genomics found a combination of five specific genes and gene expression levels present in a colorectal cancer tumor makes it high-risk and increases the risk of recurrence, according to a news release.
Using this data, Everist created the world's only molecular diagnostic test, OncoDefender-CRC, which can accurately identify tumors at high risk for recurrence among early-stage colon and rectal cancers. The test became commercially available in November, and the company has received physician requests for more than 1,000 specimen collection kits. Sanford Health Plan, which provides insurance in South Dakota, North Dakota, Iowa, Minnesota and Nebraska, has established a policy that will reimburse members for the test beginning in Jan. 2012.
Related Articles on Colorectal Cancer Screening:
Water Infusion for Cecal Intubation Increases Patient Tolerance, but not Intubation in Unsedated Colonoscopy
AGA Releases New Standards for Performing CT Colonography
Colonoscopy Best for Monitoring Mucosal Healing in Patients With Ulcerative Colitis
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
Latest Articles
- 10 Surgery Centers Currently Under Construction
- ASC Industry Leader to Know: Stephen Rosenbaum of Interventional Management Services
- 27% of Participating Orthopedic Residents Impaired by Lack of Sleep at Harvard Hospitals
- Cheyenne Eye Clinic Introduces Laser Surgery Equipment
- Malcolm Grow Medical Clinic Transitions to Air Force's First Ambulatory Surgery Center
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,502.81 Trade time:4:04PM EDT Value change:▼1.67 (-0.01%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,839.08 Trade time:5:16PM EDT Value change:▼8.13 (-0.29%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,316.63 Trade time:4:32PM EDT Value change:▲0.64 (0.05%)Channels
